Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Adrenoleukodystrophy: molecular pathogenesis and development of therapeutic agents].

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan - 1 Jul 2007

Morita Masashi

Abstract excerpt

Adrenoleukodystrophy (ALD) is an inherited disorder characterized by progressive demyelination of the central nervous system and adrenal dysfunction. The biochemical characterization is made based on the accumulation of pathognomonic amounts of saturated very long chain fatty acid (VLCFA, >22) in all tissues, including brain white matter and adrenal glands. The accumulation of VLCFA is linked to a mutation in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal Glands
Share to Adrenoleukodystrophy
Share to ATP Binding Cassette Transporter, Subfamily D, Member 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Coenzyme A Ligases

Share to Drug Design

Share to Flavanones

Share to Flavonoids

Share to Peroxisomes

Source

Identifiers

PMID: 17603264
DOI: 10.1248/yakushi.127.1059

Genes

ABCD1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Adrenoleukodystrophy: molecular pathogenesis and development of therapeutic agents].PMID 17603264Read ↗

Management of adrenoleukodystrophy: From pre-clinical studies to the development of new therapies.Semantic proximity Read ↗

X-linked adrenoleukodystrophy: pathogenesis and treatment.Semantic proximity Read ↗

From gene to therapy: a review of deciphering the role of ABCD1 in combating X-Linked adrenoleukodystrophy.Semantic proximity Read ↗

Management of adrenoleukodystrophy: From pre-clinical studies to the development of new therapiesSemantic proximity Read ↗

ABCD1 and X-linked adrenoleukodystrophy: A disease with a markedly variable phenotype showing conserved neurobiology in animal models.Semantic proximity Read ↗

[X-linked adrenoleukodystrophy].Semantic proximity Read ↗

Adrenoleukodystrophy: Current understanding of disease mechanisms, diagnosis, and therapeutic advances-a recent review.Semantic proximity Read ↗

Endocrine Dysfunction in X-Linked Adrenoleukodystrophy.Semantic proximity Read ↗

X-linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies.Semantic proximity Read ↗

X-linked adrenoleukodystrophy: clinical, biochemical and pathogenetic aspects.Semantic proximity Read ↗

X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management.Semantic proximity Read ↗

X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.